Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Irinotecan in HER2+ Advanced Colorectal Cancer
NCT00003995Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 1999
- Primary completion
- Mar 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Sep 1999; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00003995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003995.